CNTX logo

CONTEXT THERAPEUTICS INC

CNTXNASDAQ
🏆 #4605 by market capEarnings Nov 11US Equity
$0.21▼ $0.02 (−9.97%)
🌅 Pre-market$0.21▼ 0.33%Regular close · extended-hours price shown
🔔
Track CNTX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 10.0%
7d▼ 8.5%
14d▼ 11.8%
30d▼ 33.6%
ytd▼ 85.5%
1y▼ 81.5%
🏦Market Cap
$19M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.21 – $0.24
52-Week Range
$0.22 – $3.62
Volume (shares)
1,526,506
Avg Volume (shares)
—
Shares Outstanding
91.9M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-0.48
Dividend Yield
—
Dilution (1yr)
+57.3%
CNTX logo

CONTEXT THERAPEUTICS INC

CNTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$40M▲ +32.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$26M▼ −9.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
91.9M▲ +57.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$66M▼ −$28M YoY
StockOtter · stockotter.space

About CONTEXT THERAPEUTICS INC

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Buy
16 analysts
Strong Buy4
Buy11
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

Zacks Investment Research·14d ago

New Strong Sell Stocks for October 15th

CDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.

Zacks Investment Research·16d ago

New Strong Sell Stocks for October 13th

ATS, CANG and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2026.

GlobeNewsWire·Sep 9

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept.

GlobeNewsWire·Aug 5

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027